# Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

> **NCT06644313** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 31 (estimated)

## Conditions studied

- Potentially Resectable MET-altered Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Vebreltinib

## Key facts

- **NCT ID:** NCT06644313
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2029-11-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644313, "Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06644313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*